Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/druaCduTtWCcdngbCidawyCicNQoxu
| Today's Top Story |  |  | |  | Maximize Your Business's Potential.
Choose the American Express OPEN® Charge Card that's right for your established business.
• Purchasing Power
• Savings on business expenses
• Cash flow flexibility
• More rewards
American Express OPEN®. Apply Now. |
  - Study links gene mutation to rare immune disease
A study in the New England Journal of Medicine found that a mutation of the phospholipase C-gamma2 gene triggers a rare immune disease whose symptoms include cold urticaria, immune deficiency and inflammatory skin diseases. NIH researchers called the immune disease PLCG2-associated antibody deficiency and immune dysregulation. HealthDay News (1/11)       - Woman with 3 autoimmune disorders says stem cell transplant helps
Cristy Kessler, a University of Hawaii associate professor who suffered from three autoimmune diseases -- scleroderma, vasculitis and ankylosing spondylitis -- said her condition greatly improved after she underwent a stem cell transplant in Turkey that is not approved in the U.S. Kessler is on antibiotics, but she no longer needs pain drugs. KITV-TV (Honolulu) (1/11)  | How will IM, video, telephony and other elements of UC change in the coming year? This set of products provides a consistent unified user interface and experience and is poised to become more widespread in the enterprise. Get insight from Focus Experts as they share their predictions for Unified Communications in this free guide. |
 - Sanofi integrating, learning from Genzyme
Sanofi is streamlining its operations after its purchase of Genzyme, CEO Christopher Viehbacher said at the annual JPMorgan Chase Healthcare Conference. Genzyme's labs will be maintained and a Sanofi research facility in New Jersey will be closed. "Genzyme's having a big impact on the Sanofi culture," Viehbacher said. Genzyme is good at testing targets early to ensure success, he said, and "that's a skill the industry is going to need to have." The Boston Globe (tiered subscription model) (1/11) - Global venture capital group to invest $200M in biotech firms
Canaan Partners said it will allot a third of its new investment fund worth $600 million to medical device, diagnostics and biopharmaceutical firms. The global investment group is eyeing medtech ventures focused on novel devices for treating major conditions, minimally invasive therapy systems and other areas. MedCityNews.com (1/10) - Hydra hits $5M milestone for pain and inflammation drug
Cubist Pharmaceuticals and Hydra Biosciences expect to begin this quarter a Phase I study for the Hydra's experimental human Transient Receptor Potential Ankyrin repeat 1 ion channel drug for treatment of acute pain and inflammation. The trial triggers the payment of $5 million in milestone fees from Cubist to Hydra. Mass High Tech (Boston) (1/10)  | Developments in the Use of PAT and Laboratory Automation
Technical breakthroughs for better understanding and characterization of chemical or biochemical processes are key to meet today’s industry challenges. Integration of process analyzers and process automation with multivariate tools for design, data acquisition and analysis is critical. Register for the webinar. |
 | Industry Deals | | | |
| Food & Agriculture | | | | - Maine board allows two new biotech corn products
Maine's pesticide control board voted 6-1 to allow Optimum AcreMax and Optimum AcreMax Xtra insect-resistant corn from Pioneer Hi-Bred International to be planted in the state. The approval brings the number of biotech products with insecticidal genetic traits permitted to be grown in Maine to 21. Kennebec Journal (Maine) (1/10) | Industrial & Environmental | | | | - Demand for E85 in Midwestern states rose in 2011, groups say
Sales of E85 in Iowa, Minnesota and North Dakota in 2011 were markedly higher than in 2010, according to the American Lung Association and the Iowa Renewable Fuels Association. The increased sales were driven primarily by growing public awareness of ethanol and rising demand for clean, homegrown biofuels, the groups said. EthanolProducer.com (1/11) | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.
| SmartQuote | | | |  | Each morning when I open my eyes I say to myself: I, not events, have the power to make me happy or unhappy today."
--Groucho Marx,
American comedian  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, January 11, 2012
- Tuesday, January 10, 2012
- Monday, January 09, 2012
- Friday, January 06, 2012
- Thursday, January 05, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment